Concert Pharmaceuticals ROA 2024

Concert Pharmaceuticals Aktienanalyse

What does Concert Pharmaceuticals do?

Concert Pharmaceuticals Inc was founded in 2006 and is based in Lexington, Massachusetts. The company is engaged in the discovery and development of innovative drugs for the treatment of serious diseases. The goal is to explore and bring to market novel therapeutic approaches to help people with medical needs. The company has a unique business model that focuses on the use of patented deuterosome technologies and other proprietary methods. These technologies allow Concert Pharmaceuticals to modify and alter the properties of existing drugs. This enables the development of new products that either have higher efficacy or produce fewer adverse effects in patients. One of Concert Pharmaceuticals' key areas is neurological disorders. Here, the company focuses its research on the treatment of diseases such as Alzheimer's, schizophrenia, depression, and pain. In addition, Concert Pharmaceuticals also has projects in other areas, such as the treatment of respiratory diseases, cancer, or metabolic disorders. One of the best-known products of Concert Pharmaceuticals is the drug CTP-543 for the treatment of alopecia areata or patchy hair loss. The condition, which causes sudden and massive hair loss, can be very distressing and poses a major challenge, as there is currently no effective treatment method known. CTP-543 was designated as an orphan drug by the FDA (Food and Drug Administration) in the United States in 2020. This means that it is a drug that is used to treat a rare disease and is financially supported by the FDA. The company hopes that the medication will soon be available on the market and can help those affected to improve their quality of life. Concert Pharmaceuticals also has a collaboration with Celgene Corporation, an internationally active biotechnology company. Together, they aim to develop drugs that can help in the treatment of cancer. This collaboration is intended to accelerate scientific and technological advancements. The goal is to help patients faster and more effectively. Overall, Concert Pharmaceuticals employs around 120 people and has a number of patents and scientific publications to its name in recent years. The company collaborates with many renowned institutions and research facilities worldwide to find the best possible solutions in drug development. In summary, Concert Pharmaceuticals Inc is a very innovative company in the field of drug development. In addition to neurological research, the company also has projects in other areas. With its unique business model and the use of patented technologies, Concert Pharmaceuticals has the potential to develop new and effective drugs in the future, thereby improving the lives of many people worldwide. Concert Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROA Details

Understanding Concert Pharmaceuticals's Return on Assets (ROA)

Concert Pharmaceuticals's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Concert Pharmaceuticals's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Concert Pharmaceuticals's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Concert Pharmaceuticals’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Concert Pharmaceuticals Stock

What is the Return on Assets (ROA) of Concert Pharmaceuticals this year?

The Return on Assets (ROA) of Concert Pharmaceuticals is -0.48 undefined this year.

What was the ROA of Concert Pharmaceuticals compared to the previous year?

The ROA of Concert Pharmaceuticals has increased by 0% compared to the previous year.

What consequences do high ROA have for investors of Concert Pharmaceuticals?

A high ROA is advantageous for investors of Concert Pharmaceuticals, as it indicates that the company efficiently utilizes its assets and generates good profits.

What are the consequences of low ROA for investors in Concert Pharmaceuticals?

A low ROA can be unfavorable for investors of Concert Pharmaceuticals as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.

How does an increase in the ROA of Concert Pharmaceuticals affect the company?

An increase in ROA of Concert Pharmaceuticals can be an indicator of improved efficiency in asset utilization and higher profitability.

How does a reduction in ROA of Concert Pharmaceuticals impact the company?

A reduction in the ROA of Concert Pharmaceuticals can be an indicator of lower asset efficiency and profitability.

What are some factors that can influence the ROA of Concert Pharmaceuticals?

Some factors that can influence the ROA of Concert Pharmaceuticals include revenue, operating costs, asset structure, and industry average.

Why is the ROA of Concert Pharmaceuticals important for investors?

The ROA of Concert Pharmaceuticals is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.

What strategic measures can Concert Pharmaceuticals take to improve ROA?

To improve ROA, Concert Pharmaceuticals can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.

How much dividend does Concert Pharmaceuticals pay?

Over the past 12 months, Concert Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Concert Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Concert Pharmaceuticals?

The current dividend yield of Concert Pharmaceuticals is .

When does Concert Pharmaceuticals pay dividends?

Concert Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Concert Pharmaceuticals?

Concert Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Concert Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Concert Pharmaceuticals located?

Concert Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Concert Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Concert Pharmaceuticals from 6/19/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/19/2024.

When did Concert Pharmaceuticals pay the last dividend?

The last dividend was paid out on 6/19/2024.

What was the dividend of Concert Pharmaceuticals in the year 2023?

In the year 2023, Concert Pharmaceuticals distributed 0 USD as dividends.

In which currency does Concert Pharmaceuticals pay out the dividend?

The dividends of Concert Pharmaceuticals are distributed in USD.